Team Xarelto of Bayer Pharmaceuticals during the successful first ACE Summit in the Philippines Team
FILIPINO patients suffering from coronary artery disease or peripheral artery disease (CAD/PAD) may no longer need to look further to reduce their risk of major adverse cardiovascular events as a lower dosage of rivaroxaban has been introduced in the country for the new indication along with aspirin. This indication was approved by the Food and Drug Administration (FDA) last year and now made available starting this month.